Our mission is to identify and develop the most viable
The term "Cross-Functional" is used to describe Non-FDA Approved indications, also known as "Extra-Label"
or "Off-Label" Indications. By identifying and developing the most commonly used modalities, this process
will enable a more secure outcome and diversified platform for use in both the Human and Animal Healthcare
Markets with the objective of Globalizing each product in over 25 countries worldwide.
pipeline of Matured and Innovative drugs in the global healthcare market. By implementing our proprietary NSB
“C.I.D.D. Collaborative is a strategy to Consolidate, Identify, Develop, and Deploy critical medications needed to treat unmet Human patient needs."
it will ensure our core critical products are available to treat unmet Human patient needs.